Unraveling structural requirements of amino-pyrimidine T790M/L858R double mutant EGFR inhibitors: 2D and 3D QSAR study

被引:3
作者
Fatima, Shehnaz [1 ]
Agarwal, Subhash Mohan [1 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, 1-7,Sect 39, Noida 201301, India
关键词
EGFR; double mutant inhibitor; QSAR; TMLR; CELL LUNG-CANCER; DRUG-RESISTANCE; MODEL; MUTATION; DESIGN;
D O I
10.1080/10799893.2018.1494740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
EGFR is an important drug target in cancer. However, the ineffectiveness of first generation inhibitors due to the occurrence of a secondary mutation (T790M) results in the relapse of the disease. Identification of reversible inhibitors against T790M/L858R double mutants (TMLR) thus is a foremost requirement. In this study, various 2 D and 3 D Quantitative Structure-Activity Relationship models were built for amino-pyrimidine compounds with their known biological activity against TMLR mutants. The model developed using multiple linear regression statistical method via stepwise forward-backward variable selection technique showed the best results in terms of internal and external predictivity. The 2D-QSAR model indicated that the presence of electronegative atom, H-bond donors, moderate slogp, count of number of N atoms separated from O (T_N_O_4), 4pathClusterCount and number of S atom connected with two single bonds (SssSE-index), is required for increasing the inhibitory potential of compounds. Also, the 3D-QSAR model suggested that electronegative group at certain positions along with the presence of bulky groups is beneficial for good inhibition activity of the compounds. Thus, the QSAR models developed in the present work can be used for predicting the TMLR bioactivity of a new series of amino-pyrimidine derivatives. To the best of the author's knowledge, this is the first study which deals with the development of 2 D and 3D-QSAR models for double mutant TMLR inhibitors.
引用
收藏
页码:299 / 306
页数:8
相关论文
共 26 条
[1]   Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants [J].
Agarwal, Subhash Mohan ;
Pal, Divyani ;
Gupta, Mansi ;
Saini, Ravi .
CURRENT CANCER DRUG TARGETS, 2017, 17 (07) :617-636
[2]   Discovery of a Noncovalent, Mutant-Selective Epidermal Growth Factor Receptor Inhibitor [J].
Chan, Bryan K. ;
Hanan, Emily J. ;
Bowman, Krista K. ;
Bryan, Marian C. ;
Burdick, Daniel ;
Chan, Emily ;
Chen, Yuan ;
Clausen, Saundra ;
Dela Vega, Trisha ;
Dotson, Jennafer ;
Eigenbrot, Charles ;
Elliott, Richard L. ;
Heald, Robert A. ;
Jackson, Philip S. ;
Knight, Jamie D. ;
La, Hank ;
Lainchbury, Michael D. ;
Malek, Shiva ;
Purkey, Hans E. ;
Schaefer, Gabriele ;
Schmidt, Stephen ;
Seward, Eileen M. ;
Sideris, Steve ;
Shao, Lily ;
Wang, Shumei ;
Yeap, Siew Kuen ;
Yen, Ivana ;
Yu, Christine ;
Heffron, Timothy P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (19) :9080-9093
[3]   QSAR-Based Models for Designing Quinazoline/Imidazothiazoles/Pyrazolopyrimidines Based Inhibitors against Wild and Mutant EGFR [J].
Chauhan, Jagat Singh ;
Dhanda, Sandeep Kumar ;
Singla, Deepak ;
Agarwal, Subhash M. ;
Raghava, Gajendra P. S. .
PLOS ONE, 2014, 9 (07)
[4]   Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC [J].
Chen, Lingfeng ;
Fu, Weitao ;
Feng, Chen ;
Qu, Rong ;
Tong, Linjiang ;
Zheng, Lulu ;
Fang, Bo ;
Qiu, Yinda ;
Hu, Jie ;
Cai, Yuepiao ;
Feng, Jianpeng ;
Xie, Hua ;
Ding, Jian ;
Liu, Zhiguo ;
Liang, Guang .
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 140 :510-527
[5]   Personalized Cancer Medicine: Molecular Diagnostics, Predictive Biomarkers, and Drug Resistance [J].
de Castro, D. Gonzalez ;
Clarke, P. A. ;
Al-Lazikani, B. ;
Workman, P. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 (03) :252-259
[6]   NPred: QSAR classification model for identifying plant based naturally occurring anti-cancerous inhibitors [J].
Dhiman, Kanika ;
Agarwal, Subhash Mohan .
RSC ADVANCES, 2016, 6 (55) :49395-49400
[7]   Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer [J].
Engel, Julian ;
Lategahn, Jonas ;
Rauh, Daniel .
ACS MEDICINAL CHEMISTRY LETTERS, 2016, 7 (01) :2-5
[8]   Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection [J].
Golbraikh, A ;
Tropsha, A .
MOLECULAR DIVERSITY, 2000, 5 (04) :231-243
[9]   Discovery of Selective and Noncovalent Diaminopyrimidine-Based Inhibitors of Epidermal Growth Factor Receptor Containing the T790M Resistance Mutation [J].
Hanan, Emily J. ;
Eigenbrot, Charles ;
Bryan, Marian C. ;
Burdick, Daniel J. ;
Chan, Bryan K. ;
Chen, Yuan ;
Dotson, Jennafer ;
Heald, Robert A. ;
Jackson, Philip S. ;
La, Hank ;
Lainchbury, Michael D. ;
Malek, Shiva ;
Purkey, Hans E. ;
Schaefer, Gabriele ;
Schmidt, Stephen ;
Seward, Eileen M. ;
Sideris, Steve ;
Tam, Christine ;
Wang, Shumei ;
Yeap, Siew Kuen ;
Yen, Ivana ;
Yin, Jianping ;
Yu, Christine ;
Zilberleyb, Inna ;
Heffron, Timothy P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (23) :10176-10191
[10]   Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study [J].
Heald, Robert ;
Bowman, Krista K. ;
Bryan, Marian C. ;
Burdick, Daniel ;
Chan, Bryan ;
Chan, Emily ;
Chen, Yuan ;
Clausen, Saundra ;
Dominguez-Fernandez, Belen ;
Eigenbrot, Charles ;
Elliott, Richard ;
Hanan, Emily J. ;
Jackson, Philip ;
Knight, Jamie ;
La, Hank ;
Lainchbury, Michael ;
Malek, Shiva ;
Mann, Sam ;
Merchant, Mark ;
Mortara, Kyle ;
Purkey, Hans ;
Schaefee, Gabriele ;
Schmidt, Stephen ;
Seward, Eileen ;
Sideris, Steve ;
Shao, Lily ;
Wang, Shumei ;
Yeap, Kuen ;
Yen, Ivana ;
Yu, Christine ;
Heffron, Timothy P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (22) :8877-8895